PubMed Health⌕ Search

PubMed · 14768728

Intraoperative MR imaging.

Abstract

Intraoperative MR imaging has become a safe and effective technology that has revolutionized the way neurosurgery is performed. Benefits include the ability to update data sets for navigational systems, to monitor tumor resections, to adjust the approach to intracranial lesions, and to guide functional and drug or cell delivery procedures. Use of this technique can help avoid inadvertent injury of important anatomic and vascular structures. In addition, complications such as ischemia or hemorrhage can be detected early. Intraoperative MR imaging is particularly useful for ensuring that brain biopsies yield diagnostic tissue and for assessing the completeness of tumor resection. As is true for any new technology, the benefits of intraoperative MR imaging must be examined carefully to guarantee appropriate use. Many neurosurgical procedures do not require real-time image guidance and can be performed safely using current surgical techniques, including microsurgical methods and frameless and frame-based stereotaxy. Other tumor resections, tumor biopsies, and surgical and interventional procedures distinctly benefit from the sophisticated information provided by intraoperative imaging techniques. In surgery for low-grade gliomas, intraoperative MR imaging has found general acceptance, whereas its usefulness to monitor the resection of high-grade gliomas remains controversial. The economic issues related to intraoperative MR imaging cannot be overlooked. The acquisition of an intraoperative MR imaging system is associated with considerable expense, and its performance increases the cost of equipment and the operating time. Despite these additional expenses, intraoperative MR imaging can lead to a potential overall cost reduction in the treatment of certain patients if long-term cure can be achieved, repeat resection can be avoided, or procedure-associated morbidity can be reduced. Although intraoperative MR imaging techniques hold tremendous potential, the definition of their appropriate role in the delivery of successful and cost-effective medical care awaits further study.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sabine Fenchel, Daniel T Boll, Jonathan S Lewin. 2003. Intraoperative MR imaging.. https://doi.org/10.1016/s1064-9689(03)00059-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A MAGIBU-based model for pediatric and juvenile CNS tumors: an in-house epigenetic decision-support framework compared with online DNA methylation classifiers.

Background: DNA methylation profiling is a tool that provides key support for central nervous system (CNS) tumor classification. However, diagnostically ambiguous pediatric cases may result in discordant outputs across classifiers. We developed MAGIBU, a cross-platform, projection-based framework that embeds individual methylomes into a fixed CNS reference landscape, ranking diagnostic entities by local epigenetic proximity to support clinician-led integrative diagnosis. Methods: As a proof-of-concept, we evaluated MAGIBU in eight morphologically challenging pediatric/juvenile CNS tumors with unresolved diagnoses after institutional and central pathology review. To establish a benchmark in the absence of a definitive histopathological ground truth, a consensus epigenetic reference was defined a priori for cases showing concordant results between the Heidelberg CNS Tumor Methylation Classifier and Methylscape Analysis. Comparisons were also performed with Epigenomic Digital Pathology (EpiDiP). To validate MAGIBU beyond this discovery cohort, performance was assessed at the family level across the CNS methylation spectrum (n = 678, 28 methylation families), on non-array platforms (whole-genome bisulfite sequencing and Oxford Nanopore), and in a focused analysis of the low-grade glioma and diffuse midline glioma compartment across four independent cohorts (n = 670). Results: In the discovery cohort, MAGIBU achieved high concordance with the consensus reference (Cohen's κ = 0.855), outperforming EpiDiP (κ = 0.278), which frequently placed low-grade tumors in proximity to higher-grade reference regions. Conclusions: MAGIBU provides a stable, quantitative differential diagnosis framework that mitigates the limitations of rigid categorical assignments. By leveraging a distance-based proximity metric, it offers a transparent decision-support tool that integrates effectively with clinical, radiological, and molecular data. While performance is inherently dependent on reference atlas composition, MAGIBU represents a robust complementary approach for the diagnostic workup of ambiguous CNS tumors.

Brain↗

1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans.

Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088 non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only) between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and somewhat larger in deletion carriers-the latter potentially mediated by ICV or cortical surface area. These results shed light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on specific brain structures and effect on cognitive function.

Brain↗